DE102012013860A1 - New trypanosome, useful e.g. as vaccine for treating humans and/or animals against e.g. malaria, does not comprise complete functional genome, preferably trypanosome with reduced, incomplete parasitic trypanosomal DNA - Google Patents
New trypanosome, useful e.g. as vaccine for treating humans and/or animals against e.g. malaria, does not comprise complete functional genome, preferably trypanosome with reduced, incomplete parasitic trypanosomal DNA Download PDFInfo
- Publication number
- DE102012013860A1 DE102012013860A1 DE201210013860 DE102012013860A DE102012013860A1 DE 102012013860 A1 DE102012013860 A1 DE 102012013860A1 DE 201210013860 DE201210013860 DE 201210013860 DE 102012013860 A DE102012013860 A DE 102012013860A DE 102012013860 A1 DE102012013860 A1 DE 102012013860A1
- Authority
- DE
- Germany
- Prior art keywords
- trypanosomes
- dna
- nebenanspruch
- trypanosome
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003071 parasitic effect Effects 0.000 title claims abstract description 7
- 229960005486 vaccine Drugs 0.000 title claims abstract description 5
- 241001465754 Metazoa Species 0.000 title claims description 10
- 201000004792 malaria Diseases 0.000 title claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 230000014509 gene expression Effects 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 230000035605 chemotaxis Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 108010023197 Streptokinase Proteins 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 229960005202 streptokinase Drugs 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 210000003705 ribosome Anatomy 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004292 cytoskeleton Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000000078 anti-malarial effect Effects 0.000 abstract 1
- 239000003430 antimalarial agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000002423 protozoacide Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 229940124735 malaria vaccine Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 208000000230 African Trypanosomiasis Diseases 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 241001136792 Alle Species 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241001502121 Glossina brevipalpis Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000222712 Kinetoplastida Species 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 101001092135 Plasmodium falciparum (isolate 3D7) Reticulocyte-binding protein homolog 5 Proteins 0.000 description 2
- 101000983333 Plasmodium falciparum (isolate NF54) 25 kDa ookinete surface antigen Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 241000223105 Trypanosoma brucei Species 0.000 description 2
- 101150078331 ama-1 gene Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002498 deadly effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000029080 human African trypanosomiasis Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 244000309459 oncolytic virus Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 201000002612 sleeping sickness Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 1
- 206010001854 Altered state of consciousness Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102100033183 Epithelial membrane protein 1 Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000850989 Homo sapiens Epithelial membrane protein 1 Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- -1 Pfs230C Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000001099 anti-trypanosomal effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 210000003936 merozoite Anatomy 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000025608 mitochondrion localization Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108091023023 pteridine reductase Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000013715 transcription antitermination Effects 0.000 description 1
- 239000002690 trypanocidal agent Substances 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/10—Protozoa; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Hintergrund der ErfindungBackground of the invention
Die einzelligen Trypanosomen (Klasse Kinetoplastida) sind die Erreger der Afrikanischen Schlafkrankheit, die unbehandelt tödlich verläuft. Das Stadium I (Hämolymphatische Phase; Lymphknotenschwellung) bleibt zunächst oft unerkannt. Nach dem Biss einer infizierten Tsetsefliege beträgt das Risiko etwa 1:100. Nach Monaten tritt in der Regel das Stadium II (Meningoenzephalitische Phase) auf. Bei der insgesamt rascher und virulenter verlaufenden Infektion mit T. b. rhodesiense kann dies auch bereits nach wenigen Wochen der Fall sein. Das Stadium II geht mit zunehmenden Verwirrungszuständen, Koordinations- und Schlafstörungen, Krampfanfällen, Apathie und Gewichtsverlust einher. Im Endstadium fallen die Patienten in einen kontinuierlichen Dämmerzustand, der der Krankheit ihren Namen gegeben hat. Im Liquor cerebrospinalis ist eine Zellvermehrung nachweisbar. Letztlich endet die Krankheit tödlich (
Die Erfindung betrifft damit Aspekte der synthetischen Biologie, nämlich die Erzeugung von modifizierten Organismen mit dem Ziel, eine medizinische günstige Verwendung zu erreichen. Wir wollen parasitische Trypanosomen, deren DNA spezifisch reduziert wurde, als therapeutische oder diagnostische Systeme in Mensch bzw. Tier einsetzen. Ein Ausführungsbeispiel verwendet hierzu ein DNAse-Gen, das durch ein induzierbares, molekularbiologisches Konstrukt in den Trypanosomen exprimiert wurde. Nach Induktion des Gens und Produktion des DNA-zerstörenden Enzyms, werden mittels Zellsortierung DNA-arme Trypanosomen isoliert. Diese können weiter transformiert und modifiziert werden und stehen dann für diagnostische und therapeutische Anwendungen als selbst bewegliche, vom Immunsystem nicht erkannte Vehikel zur Verfügung (therapeutisches System, z. B. Generierung einer Malariavakzine).The invention thus relates to aspects of synthetic biology, namely the production of modified organisms with the aim of achieving a medicinally favorable use. We want to use parasitic trypanosomes whose DNA has been specifically reduced as therapeutic or diagnostic systems in humans or animals. One embodiment uses for this purpose a DNAse gene expressed in the trypanosomes by an inducible molecular biology construct. After induction of the gene and production of the DNA-destroying enzyme, DNA-poor trypanosomes are isolated by cell sorting. These can be further transformed and modified and are then available for diagnostic and therapeutic applications as a self-agile, immune system-unrecognized vehicle (therapeutic system, eg, generation of a malaria vaccine).
Stand der Technik und technisches ProblemState of the art and technical problem
Therapeutische Vektorsysteme wurden schon vielfach untersucht (
Lösung: Hier setzt unsere Erfindung ein, denn Trypanosomen sind optimale Vehikel wenn es darum geht, länger unerkannt im Blutstrom zu verweilen. Zudem bringen sie eigene aktive und auch steuerbare Beweglichkeit mit. Von einem relativ neuen Forschungsfeld, der synthetischen Biologie, kommt der Ansatz Organismen nur mit einem minimalem Genom auszustatten, um damit zu gewährleisten, dass nur die essentiellen Überlebensgene vom Organismus selbst kommen und die übrigen Genomteile dann nach Wunsch ersetzt werden, um zusätzliche medizinisch oder biotechnologisch gewünschte Leistungen zu erreichen. Dies ist aber zurzeit nur für sehr kleine bakterielle Lebewesen möglich (
Beschreibung der ErfindungDescription of the invention
Erfindungsgemäß wird die Elimination der unnötigen Gene der Trypanosomen wesentlich umfassender und radikaler gelöst:
Transgene Trypanosomen beinhalten ein Konstrukt mit induzierbarem Promotor, bei Zugabe des Induktors im Kulturmedium (z. B. optimiertes Standardkulturmedium für Trypanosomen (
Transgenic trypanosomes include an inducible promoter construct upon addition of the inducer in the culture medium (eg, optimized standard trypanosomal culture medium (
Ausführungsbeispiel: Dagegen ist aber im Ausführungsbeispiel die erfindungsgemäße Induktion einer DNAse (
Für eine therapeutische oder diagnostische Nutzung werden DNAse-positive Trypanosomen aus der Kultur mit einem Cell-Sorter selektiert, so dass in Versuchstiere bzw. Patienten nur Trypanosomen gelangen, bei denen die DNA im Zellkern bereits erheblich oder vollständig zerstört wurde, so dass keine parasitäre Gefahr mehr von ihnen ausgeht. Dies wird zudem durch Tierversuche nachgewiesen.For therapeutic or diagnostic use, DNAse-positive trypanosomes are selected from the culture with a cell sorter so that only trypanosomes are obtained in experimental animals or patients in which the DNA in the nucleus has already been significantly or completely destroyed, so that no parasitic danger more of them goes out. This is also demonstrated by animal experiments.
Weitere Ausgestaltung der ErfindungFurther embodiment of the invention
Das Ausführungsbeispiel nutzt und exprimiert also das Fremdprotein des Konstrukts in Trypanosomen. Das Konstrukt und die DNAse exprimierenden Trypanosomen werden über GFP (
Detaillierte Beschreibung der Figuren:
Erwünschte genetische Information kann nun außerdem in den Trypanosomen über spezielle DNA Konstrukte eingeschleust werden, die durch geeignete Methylierung etc. gegen die induzierte DNAse resistent sind. Auf diese Weise kann man dann ein sehr interessantes minimales Genom erzeugen, nämlich eines, das die transgenen Trypanosomen für eine genau definierte Zeit und ein exakt vorhersagbares Funktionsspektrum überleben lässt. Dies ist auch theoretisch von hohem Interesse, da es wieder zeigt, dass die Definition eines minimalen Genoms sehr umweltabhängig ist und wir hier mit minimalen Genomen arbeiten, die nur noch wenig erwünschte Funktionen der Trypanosomen aufrecht erhalten, aber weit unter der für eine erfolgreiche Replikation nötigen genetischen Information liegen.Desired genetic information can now also be introduced into the trypanosomes via specific DNA constructs that are resistant to the induced DNAse by appropriate methylation, etc. In this way, one can then generate a very interesting minimal genome, one that allows the transgenic trypanosomes to survive for a well-defined time and an accurately predictable spectrum of functions. This is also theoretically of great interest because it shows once again that the definition of a minimal genome is very environmentally dependent and we are working with minimal genomes that have little to do with it maintain desirable functions of the trypanosomes but are well below the genetic information necessary for successful replication.
Vorteile und Nutzungsmöglichkeiten der DNA-armen Trypanosomen (Tabelle 1):Advantages and uses of DNA-poor trypanosomes (Table 1):
- a) Beispielsweise kann man die Trypanosomen ein Wunschprotein exprimieren lassen und dies sehr rasch im Blutstrom verteilen. Ebenso gilt das für ein Wunschtoxin (Antibiotikum, Zytostatikum, Hormon, Antikoagulans wie Streptokinase etc.). Dabei kann das effiziente Sekretionssystem der Trypanosomen (für VSG) mit Gewinn genutzt werden.a) For example, one can have the trypanosomes express a protein of interest and distribute this very quickly in the bloodstream. This also applies to a desired toxin (antibiotic, cytostatic, hormone, anticoagulant such as streptokinase etc.). The efficient secretion system of trypanosomes (for VSG) can be used profitably.
-
b) Eine wichtige Hauptanwendung ist die Herstellung eines Malariaimpfstoffes. Sehr vorteilhaft ist insbesondere die folgende Strategie:
Expression der beiden Oberflächenproteine MSP1 (merozoitenspezifische) und AMA1 (hochpolymorph). Gegen Malaria (
Hill, 2011 Hill, 2011 -
c) Veterinärmedizinische Anwendung: African Animal Trypanosomiasis (AAT): Eine ganze Reihe von Trypanosomen parasitieren in Pferden, Schweinen, Ziegen und besonders in Rindern. Die Übertragung kann durch die Tsetsefliege oder auch mechanisch erfolgen. Die Tierseuche Nagana ist ein immenses ökonomisches Problem in Afrika (
Magez et al., 2010 Magez et al., 2010
Die Anwendung auf tierpathogene Trypanosomen erlaubt das Funktionsprinzip zu testen und die antitrypanosomalen Effekte zu quantifizieren (siehe b und c).
- d) Wichtig ist auch, dass die DNA-armen Trypanosomen über Chemotaxis intelligent steuerbar sind. Beispielsweise kann man sie mit Chemoattraktanten (spezifische Zytokine, vgl.
Boyanova et al., 2012 - e) Außerdem kann die Bewegung der DNA-armen Trypanosomen auch von außen, etwa durch Expression von GFP (grün leuchten) oder andere Marker (optisches oder anderes Signal) direkt verfolgt werden. Über Rezeptoren der Trypanosomen (z. B. unter „d”) sind diese aber auch direkt steuerbar.
- f) Die DNA-armen Trypanosomen können aber auch durch Einbringen von geeigneten Genen auch mit Wunschsensoren ausgestattet werden, z. B. einen pH-, Sauerstoff- oder Redoxsensor (vgl. Design von zwei Komponentensystemen hierfür,
Krüger et al., 2012 - g) Das Potential solcher neuer therapeutischer bzw. diagnostischer Systeme ist enorm. Diese DNA-armen Trypanosomen kann man mit allen anderen modernen molekularbiologischen Optionen für neue Therapien bestens kombinieren (Ribozyme (
Win et al., 2008 Zhang et al., 2009 Adler et al., 2008 - h) Sehr interessant ist auch die Tatsache, dass Trypanosomen über ihre variablen Oberflächenglykoproteine alle bindenden Antikörper des Immunsystems endozytieren (ehe diese Antikörper die Immunantworten des Wirtes auslösen können). Prinzipiell können alle internalisierten Antikörper für eine schnelle Analyse des aktuellen Antikörper-Status genutzt werden und mittels GFP oder anderen Indikatoren angezeigt werden. Dies kann z. B. für den Nachweis von Autoantikörpern wie antinukleäre Faktoren genutzt werden.
- i) Selbstverständlich können die DNA-armen Trypanosomen auch zur Elimination von Wildtyp Trypanosomen genutzt werden. Eine Möglichkeit ist mit einem Genkonversions-Konstrukt (z.
B. DP DE ).10 2006 021 51 684
- d) It is also important that the DNA-poor trypanosomes are intelligently controlled via chemotaxis. For example, they can be mixed with chemoattractants (specific cytokines, cf.
Boyanova et al., 2012 - e) In addition, the movement of the DNA-poor trypanosomes can also be directly monitored from the outside, for example by expression of GFP (green light) or other markers (optical or other signal). Via receptors of the Trypanosomen (eg under "d") these are however also directly controllable.
- f) The DNA-poor trypanosomes can also be equipped by introducing appropriate genes with desire sensors, z. B. a pH, oxygen or redox sensor (see Design of two component systems for this,
Krüger et al., 2012 - g) The potential of such new therapeutic or diagnostic systems is enormous. These DNA-poor trypanosomes can be optimally combined with all other modern molecular biology options for new therapies (ribozyme (
Win et al., 2008 Zhang et al., 2009 Adler et al., 2008 - h) Very interesting is also the fact that trypanosomes endocytose all binding antibodies of the immune system via their variable surface glycoproteins (before these antibodies can trigger the immune responses of the host). In principle, all internalized antibodies can be used for rapid analysis of the current antibody status and displayed using GFP or other indicators. This can be z. B. be used for the detection of autoantibodies such as antinuclear factors.
- i) Of course, the low-DNA trypanosomes can also be used for the elimination of wild-type trypanosomes. One possibility is with a gene conversion construct (eg,
DP DE ).10 2006 021 51 684
Tabelle 1: Anwendungen – DNA-arme Trypanosomen (DAT) können u. a. verwendet werden für:
Referenzenreferences
-
Adler A, Forster N, Homann M, Göringer HU (2008). Post-SELEX chemical optimization of a trypanosome-specific RNA aptamer. Comb Chem High Throughput Screen. 11(1): 16–23 Adler A, Forster N, Homann M, Göringer HU (2008). Post-SELEX chemical optimization of a trypanosome-specific RNA aptamer. Comb Chem High Throughput Screen. 11 (1): 16-23 -
Alam Ml, Beg S, Samad A, Baboota S, Kohli K, Ali J, Ahuja A, Akbar M. Strategy for effective brain drug delivery. Eur J Pharm Sci. 2010 Aug 11; 40(5): 385–403 Alam Ml, Beg S, Samad A, Baboota S, Kohli K, Ali J, Ahuja A, Akbar M. Strategy for effective brain drug delivery. Eur J Pharm Sci. 2010 Aug 11; 40 (5): 385-403 -
Boyanova D, Nilla S, Birschmann I, Dandekar T, Dittrich M (2012) PlateletWeb: A systems biological analysis of signaling networks in human platelets. Blood 119(3): e22–34 Boyanova D, Nilla S, Birschmann I, Dandekar T, Dittrich M (2012) PlateletWeb: A systems biological analysis of signaling networks in human platelets. Blood 119 (3): e22-34 -
Chye S, Loo J, Moore T, Banik B, Alexis F. (2010) Biomedical Applications of Hydroxyapatite Nanoparticles. Curr Pharm Biotechnol. 11.4: 333–42 Chye S, Loo J, Moore T, Banik B, Alexis F. (2010) Biomedical Applications of Hydroxyapatite Nanoparticles. Curr Pharm Biotechnol. 11.4: 333-42 -
Coustou V, Guegan F, Plazolles N, Baltz T. Complete in vitro life cycle of Trypanosoma congolense: development of genetic tools. PLoSNegl Trop Dis. 2010 Mar 2; 4(3): e618. PubMed PMID: 20209144; PubMed Central PMCID: PMC2830455 Coustou V, Guegan F, Plazolles N, Baltz T. Complete in vitro life cycle of Trypanosoma congolense: development of genetic tools. PLoSNegl Trop Dis. 2010 Mar 2; 4 (3): e618. PubMed PMID: 20209144; PubMed Central PMCID: PMC2830455 -
Dönges, J. Parasitologie, 1988, 2. Aufl., Georg ThiemeVerlag, Stuttgart/New York, ISBN 3-13-579902-6Dönges, J. Parasitology, 1988, 2nd ed., Georg Thieme Verlag, Stuttgart / New York, ISBN 3-13-579902-6 -
DP
DE 10 2006 021 516 B4 DP DE Gen conversion construct and method for the inheritance of gene mobility and use of the construct (patent holder: University of Würzburg, inventor: Leo Tobias and Dandekar Thomas)10 2006 021 516 B4 -
Engstler M, Pfohl T, Herminghaus S, Boshart M, Wiegertjes G, Heddergott N, Overath P. Hydrodynamicflowmediatedproteinsorting on thecellsurfaceoftrypanosomes. Cell. 2007 Nov 2; 131(3): 505–15 Engstler M, Pfohl T, Herminghaus S, Boshart M, Wiegertjes G, Heddergott N, Overath P. Hydrodynamic flow mediated protein locating on the cell surface of trypanosomes. Cell. 2007 Nov 2; 131 (3): 505-15 -
Fu Q, Sun J, Zhang W, Sui X, Yan Z, He Z. Nanoparticlealbumin-bound (NAB) technologyis a promising methodfor anti-cancerdrugdelivery. Recent Pat Anticancer Drug Discov. 2009 Nov; 4(3): 262–72 Fu Q, Sun J, Zhang W, Sui X, Yan Z, He Z. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat Anticancer Drug Discov. 2009 Nov; 4 (3): 262-72 -
Gibson DG, Glass Jl, Lartigue C, Noskov VN, Chuang RY, Algire MA, Benders GA, Montague MG, Ma L, Moodie MM, Merryman C, Vashee S, Krishnakumar R, Assad-Garcia N, Andrews-Pfannkoch C, Denisova EA, Young L, Qi ZQ, Segall-Shapiro TH, Calvey CH, Parmar PP, Hutchison CA 3rd, Smith HO, Venter JC (2010) Creation of a bacterial cell controlled by a chemically synthesized genome. Science. 329, 52–56 Gibson DG, Glass Jl, Lartigue C, Noskov VN, Chuang RY, Algire MA, Benders GA, Montague MG, Ma L, Moodie MM, Merryman C, Vashee S, Krishnakumar R, Assad-Garcia N, Andrews Pancake C, Denisova EA, Young L, Qi ZQ, Segall-Shapiro TH, Calvey CH, Parmar PP, Hutchison CA 3rd, Smith HO, Venter JC (2010) Creation of a bacterial cell controlled by a chemically synthesized genome. Science. 329, 52-56 -
Haines LR, Thomas JM, Jackson AM, Eyford BA, Razavi M, Watson CN, Gowen B, Hancock RE, Pearson TW. Killing of trypanosomatid parasites by a modified bovine host defense peptide, BMAP-18. PLoSNegl Trop Dis. 2009; 3(2): e373. Epub 2009 Feb 3. PubMed PMID: 19190729; PubMed Central PMCID: PMC2628741 Haines LR, Thomas JM, Jackson AM, Eyford BA, Razavi M, Watson CN, Gowen B, Hancock RE, Pearson TW. Killing of trypanosomatid parasites by a modified bovine host defense peptide, BMAP-18. PLoSNegl Trop Dis. 2009; 3 (2): e373. Epub 2009 Feb 3. PubMed PMID: 19190729; PubMed Central PMCID: PMC2628741 -
Heurtault B, Frisch B, Pons F. (2010) Liposomes as delivery systems for nasal vaccination: strategies and outcomes. Expert Opin Drug Deliv. Jul; 7(7): 829–844 Heurtault B, Frisch B, Pons F. (2010) Liposomes as delivery systems for nasal vaccination: strategies and outcomes. Expert Opin Drug Deliv. July; 7 (7): 829-844 -
Hill AV. Vaccines against malaria. Philos Trans R SocLond B Biol Sci. 2011 Oct 12; 366(1579): 2806–14 Hill AV. Vaccines against malaria. Philos Trans R SocLond B Biol Sci. 2011 Oct 12; 366 (1579): 2806-14 -
Hiltensperger, G., Jones, N. G., Niedermeier, S., Stich, A., Kaiser, M., Jung, J., Puhl, S., Damme, A., Braunschweig, H., Meinel, L., Engstler, M., Holzgrabe, U. (2012). Synthesis and structure-activity relationships of new quinolone-type molecules against Trypanosoma brucei. Journal of Medicinal Chemistry 55, 2538–2548 Hiltensperger, G., Jones, NG, Niedermeier, S., Stich, A., Kaiser, M., Jung, J., Puhl, S., Damme, A., Braunschweig, H., Meinel, L., Engstler , M., Holzgrabe, U. (2012). Synthesis and structure-activity relationships of new quinolone-type molecules against Trypanosoma brucei. Journal of Medicinal Chemistry 55, 2538-2548 -
Kim T, Kang E, Chun I, Gwak H. Pharmacokinetics of formulated tenoxicam transdermal delivery systems. J Pharm Pharmacol. 2008 Jan; 60(1): 135–8. PubMed PMID: 18088513 Kim T, Kang E, Chun I, Gwak H. Pharmacokinetics of formulated tenoxicam transdermal delivery systems. J Pharm Pharmacol. 2008 Jan; 60 (1): 135-8. PubMed PMID: 18088513 -
Krueger B, Friedrich T, Förster F, Bernhardt J, Gross R, Dandekar T. (2012) Different evolutionary modifications as a guide to rewire two-component systems. Bioinform Biol Insights. 6, 97–128 Krueger B, Friedrich T, Förster F, Bernhardt J, Gross R, Dandekar T. (2012) Different evolutionary modifications as a guide to rewire two-component systems. Bioinform Biol Insights. 6, 97-128 -
Magez S, Caljon G, Tran T, Stijlemans B, Radwanska M. Current status of vaccination against African trypanosomiasis. Parasitology. 2010 Dec; 137(14): 2017–27 Magez S, Caljon G, Tran T, Stijlemans B, Radwanska M. Current status of vaccination against African trypanosomiasis. Parasitology. 2010 Dec; 137 (14): 2017-27 -
Presumey J, Duroux-Richard 1, Courties G, Apparailly F. Cationic liposome formulations for RNAi-based validation of therapeutic targets in rheumatoid arthritis. CurrOpinMolTher. 2010 Jun; 12(3): 325–30 Presumey J, Duroux-Richard 1, Courties G, Apparailly F. Cationic liposome formulations for RNAi-based validation of therapeutic targets in rheumatoid arthritis. CurrOpinMolTher. 2010 Jun; 12 (3): 325-30 -
Sienkiewicz N, Ong HB, Fairlamb AH. Trypanosoma brucei pteridinereductase 1 is essential for survival in vitro and for virulence in mice. MolMicrobiol. 2010 Jun 1. [Epub ahead of print] PubMed PMID: 20545846 Sienkiewicz N, Ong HB, Fairlamb AH. Trypanosoma brucei pteridinereductase 1 is essential for survival in vitro and for virulence in mice. MolMicrobiol. 2010 Jun 1. [Epub ahead of print] PubMed PMID: 20545846 -
Rosenkranz V, Wink M. Alkaloids induce programmed cell death in bloodstream forms of trypanosomes (Trypanosoma b. brucei). Molecules. 2008 Oct 3; 13(10): 2462–73. PubMed PMID: 18833031 Rosary V, Wink M. Alkaloids induce programmed cell death in bloodstream forms of trypanosomes (Trypanosoma b.Brcei). Molecules. 2008 Oct 3; 13 (10): 2462-73. PubMed PMID: 18833031 -
Win MN, Smolke CD. Higher-order cellular information processing with syntheticRNA devices. Science. 2008 Oct 17; 322(5900): 456–60. PubMed PMID: 18927397; PubMed Central PMCID: PMC2805114 Win MN, Smolke CD. Higher-order cellular information processing with synthetic RNA devices. Science. 2008 Oct 17; 322 (5900): 456-60. PubMed PMID: 18927397; PubMed Central PMCID: PMC2805114 -
Winkle, S: Geißeln der Menschheit – Kulturgeschichte der Seuchen. Artemis & Winkler Verlag, 3. erweiterte Auflage, 2005, ISBN 3-538-07159-4Winkle, S: Scourging Humanity - Cultural History of Plagues. Artemis & Winkler Verlag, 3rd extended edition, 2005, ISBN 3-538-07159-4 -
Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. MolTher. 2010 Feb; 18(2): 243–50. Epub 2009 Nov 24. Review. PubMed PMID: 19935777; PubMed Central PMCID: PMC2839292 Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Molther. 2010 Feb; 18 (2): 243-50. Epub 2009 Nov 24. Review. PubMed PMID: 19935777; PubMed Central PMCID: PMC2839292 -
Zhang Q, Liang C, Yu YA, Chef N, Dandekar T, Szalay AA. (2009) The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genomics 282(4): 417–35 Zhang Q, Liang C, Yu Ya, Chief N, Dandekar T, Szalay AA. (2009) The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genomics 282 (4): 417-35
ZITATE ENTHALTEN IN DER BESCHREIBUNG QUOTES INCLUDE IN THE DESCRIPTION
Diese Liste der vom Anmelder aufgeführten Dokumente wurde automatisiert erzeugt und ist ausschließlich zur besseren Information des Lesers aufgenommen. Die Liste ist nicht Bestandteil der deutschen Patent- bzw. Gebrauchsmusteranmeldung. Das DPMA übernimmt keinerlei Haftung für etwaige Fehler oder Auslassungen.This list of the documents listed by the applicant has been generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.
Zitierte PatentliteraturCited patent literature
- DE 10200602151684 [0012] DE 10200602151684 [0012]
Zitierte Nicht-PatentliteraturCited non-patent literature
- Dönges, 1988 [0001] Dönges, 1988 [0001]
- Winkle, 2005 [0001] Winkle, 2005 [0001]
- Engstler et al., 2007 [0001] Engstler et al., 2007 [0001]
- Fu et al., 2009 [0003] Fu et al., 2009 [0003]
- Heurtault et al., 2010 [0003] Heurtault et al., 2010 [0003]
- Alam et al., 2010 [0003] Alam et al., 2010 [0003]
- Presumey et al., 2010 [0003] Presumey et al., 2010 [0003]
- Yamamoto und Curiel, 2010 [0003] Yamamoto and Curiel, 2010 [0003]
- Kim et al., 2008 [0003] Kim et al., 2008 [0003]
- Chye et al., 2010 [0003] Chye et al., 2010 [0003]
- Gibson et al., 2010 [0004] Gibson et al., 2010 [0004]
- Sienkiewicz et al., 2010 [0004] Sienkiewicz et al., 2010 [0004]
- Coustou et al., 2010 [0004] Coustou et al., 2010 [0004]
- Coustou et al., 2010 [0005] Coustou et al., 2010 [0005]
- Haines et al., 2009 [0005] Haines et al., 2009 [0005]
- Rosenkranz und Wink, 2008 [0005] Rosary and Wink, 2008 [0005]
- Hiltensberger et al., 2012 [0009] Hiltensberger et al., 2012 [0009]
- Hill, 2011 [0011] Hill, 2011 [0011]
- Magez et al., 2010 [0011] Magez et al., 2010 [0011]
- Boyanova et al., 2012 [0012] Boyanova et al., 2012 [0012]
- Krüger et al., 2012 [0012] Krüger et al., 2012 [0012]
- Win et al., 2008 [0012] Win et al., 2008 [0012]
- Zhang et al., 2009 [0012] Zhang et al., 2009 [0012]
- Adler et al., 2008 [0012] Adler et al., 2008 [0012]
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE201210013860 DE102012013860A1 (en) | 2012-07-05 | 2012-07-05 | New trypanosome, useful e.g. as vaccine for treating humans and/or animals against e.g. malaria, does not comprise complete functional genome, preferably trypanosome with reduced, incomplete parasitic trypanosomal DNA |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE201210013860 DE102012013860A1 (en) | 2012-07-05 | 2012-07-05 | New trypanosome, useful e.g. as vaccine for treating humans and/or animals against e.g. malaria, does not comprise complete functional genome, preferably trypanosome with reduced, incomplete parasitic trypanosomal DNA |
Publications (1)
Publication Number | Publication Date |
---|---|
DE102012013860A1 true DE102012013860A1 (en) | 2014-01-09 |
Family
ID=49780554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE201210013860 Pending DE102012013860A1 (en) | 2012-07-05 | 2012-07-05 | New trypanosome, useful e.g. as vaccine for treating humans and/or animals against e.g. malaria, does not comprise complete functional genome, preferably trypanosome with reduced, incomplete parasitic trypanosomal DNA |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE102012013860A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2992895A1 (en) * | 2014-09-08 | 2016-03-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Three-component-multistage malaria vaccine |
US10183066B2 (en) | 2014-03-28 | 2019-01-22 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V | Multi-component-multistage malaria vaccines |
US10577412B2 (en) | 2015-04-12 | 2020-03-03 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Anti-plasmodium parasite antibodies |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006021516B4 (en) | 2006-05-04 | 2010-03-25 | Julius-Maximilians-Universität Würzburg | Gene conversion construct and method of inheriting gene mobility and use of the construct |
-
2012
- 2012-07-05 DE DE201210013860 patent/DE102012013860A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006021516B4 (en) | 2006-05-04 | 2010-03-25 | Julius-Maximilians-Universität Würzburg | Gene conversion construct and method of inheriting gene mobility and use of the construct |
Non-Patent Citations (47)
Title |
---|
Adler A, Forster N, Homann M, Göringer HU (2008). Post-SELEX chemical optimization of a trypanosome-specific RNA aptamer. Comb Chem High Throughput Screen. 11(1): 16-23 |
Adler et al., 2008 |
Alam et al., 2010 |
Alam Ml, Beg S, Samad A, Baboota S, Kohli K, Ali J, Ahuja A, Akbar M. Strategy for effective brain drug delivery. Eur J Pharm Sci. 2010 Aug 11; 40(5): 385-403 |
Boyanova D, Nilla S, Birschmann I, Dandekar T, Dittrich M (2012) PlateletWeb: A systems biological analysis of signaling networks in human platelets. Blood 119(3): e22-34 |
Boyanova et al., 2012 |
Chye et al., 2010 |
Chye S, Loo J, Moore T, Banik B, Alexis F. (2010) Biomedical Applications of Hydroxyapatite Nanoparticles. Curr Pharm Biotechnol. 11.4: 333-42 |
Coustou et al., 2010 |
Coustou V, Guegan F, Plazolles N, Baltz T. Complete in vitro life cycle of Trypanosoma congolense: development of genetic tools. PLoSNegl Trop Dis. 2010 Mar 2; 4(3): e618. PubMed PMID: 20209144; PubMed Central PMCID: PMC2830455 |
Dönges, 1988 |
Dönges, J. Parasitologie, 1988, 2. Aufl., Georg ThiemeVerlag, Stuttgart/New York, ISBN 3-13-579902-6 |
Engstler et al., 2007 |
Engstler M, Pfohl T, Herminghaus S, Boshart M, Wiegertjes G, Heddergott N, Overath P. Hydrodynamicflowmediatedproteinsorting on thecellsurfaceoftrypanosomes. Cell. 2007 Nov 2; 131(3): 505-15 |
Fu et al., 2009 |
Fu Q, Sun J, Zhang W, Sui X, Yan Z, He Z. Nanoparticlealbumin-bound (NAB) technologyis a promising methodfor anti-cancerdrugdelivery. Recent Pat Anticancer Drug Discov. 2009 Nov; 4(3): 262-72 |
Gibson DG, Glass Jl, Lartigue C, Noskov VN, Chuang RY, Algire MA, Benders GA, Montague MG, Ma L, Moodie MM, Merryman C, Vashee S, Krishnakumar R, Assad-Garcia N, Andrews-Pfannkoch C, Denisova EA, Young L, Qi ZQ, Segall-Shapiro TH, Calvey CH, Parmar PP, Hutchison CA 3rd, Smith HO, Venter JC (2010) Creation of a bacterial cell controlled by a chemically synthesized genome. Science. 329, 52-56 |
Gibson et al., 2010 |
Haines et al., 2009 |
Haines LR, Thomas JM, Jackson AM, Eyford BA, Razavi M, Watson CN, Gowen B, Hancock RE, Pearson TW. Killing of trypanosomatid parasites by a modified bovine host defense peptide, BMAP-18. PLoSNegl Trop Dis. 2009; 3(2): e373. Epub 2009 Feb 3. PubMed PMID: 19190729; PubMed Central PMCID: PMC2628741 |
Heurtault B, Frisch B, Pons F. (2010) Liposomes as delivery systems for nasal vaccination: strategies and outcomes. Expert Opin Drug Deliv. Jul; 7(7): 829-844 |
Heurtault et al., 2010 |
Hill AV. Vaccines against malaria. Philos Trans R SocLond B Biol Sci. 2011 Oct 12; 366(1579): 2806-14 |
Hill, 2011 |
Hiltensberger et al., 2012 |
Hiltensperger, G., Jones, N. G., Niedermeier, S., Stich, A., Kaiser, M., Jung, J., Puhl, S., Damme, A., Braunschweig, H., Meinel, L., Engstler, M., Holzgrabe, U. (2012). Synthesis and structure-activity relationships of new quinolone-type molecules against Trypanosoma brucei. Journal of Medicinal Chemistry 55, 2538-2548 |
Kim et al., 2008 |
Kim T, Kang E, Chun I, Gwak H. Pharmacokinetics of formulated tenoxicam transdermal delivery systems. J Pharm Pharmacol. 2008 Jan; 60(1): 135-8. PubMed PMID: 18088513 |
Krueger B, Friedrich T, Förster F, Bernhardt J, Gross R, Dandekar T. (2012) Different evolutionary modifications as a guide to rewire two-component systems. Bioinform Biol Insights. 6, 97-128 |
Krüger et al., 2012 |
Magez et al., 2010 |
Magez S, Caljon G, Tran T, Stijlemans B, Radwanska M. Current status of vaccination against African trypanosomiasis. Parasitology. 2010 Dec; 137(14): 2017-27 |
Presumey et al., 2010 |
Presumey J, Duroux-Richard 1, Courties G, Apparailly F. Cationic liposome formulations for RNAi-based validation of therapeutic targets in rheumatoid arthritis. CurrOpinMolTher. 2010 Jun; 12(3): 325-30 |
Rosenkranz und Wink, 2008 |
Rosenkranz V, Wink M. Alkaloids induce programmed cell death in bloodstream forms of trypanosomes (Trypanosoma b. brucei). Molecules. 2008 Oct 3; 13(10): 2462-73. PubMed PMID: 18833031 |
Sienkiewicz et al., 2010 |
Sienkiewicz N, Ong HB, Fairlamb AH. Trypanosoma brucei pteridinereductase 1 is essential for survival in vitro and for virulence in mice. MolMicrobiol. 2010 Jun 1. [Epub ahead of print] PubMed PMID: 20545846 |
Trypanosoma brucei brucei * |
Win et al., 2008 |
Win MN, Smolke CD. Higher-order cellular information processing with syntheticRNA devices. Science. 2008 Oct 17; 322(5900): 456-60. PubMed PMID: 18927397; PubMed Central PMCID: PMC2805114 |
Winkle, 2005 |
Winkle, S: Geißeln der Menschheit - Kulturgeschichte der Seuchen. Artemis & Winkler Verlag, 3. erweiterte Auflage, 2005, ISBN 3-538-07159-4 |
Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. MolTher. 2010 Feb; 18(2): 243-50. Epub 2009 Nov 24. Review. PubMed PMID: 19935777; PubMed Central PMCID: PMC2839292 |
Yamamoto und Curiel, 2010 |
Zhang et al., 2009 |
Zhang Q, Liang C, Yu YA, Chef N, Dandekar T, Szalay AA. (2009) The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genomics 282(4): 417-35 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10183066B2 (en) | 2014-03-28 | 2019-01-22 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V | Multi-component-multistage malaria vaccines |
EP2992895A1 (en) * | 2014-09-08 | 2016-03-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Three-component-multistage malaria vaccine |
WO2016037916A1 (en) * | 2014-09-08 | 2016-03-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Three-component-multistage malaria vaccine |
US10213501B2 (en) | 2014-09-08 | 2019-02-26 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Three-component-multistage malaria vaccine |
US10577412B2 (en) | 2015-04-12 | 2020-03-03 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Anti-plasmodium parasite antibodies |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hunt et al. | GABA progenitors grafted into the adult epileptic brain control seizures and abnormal behavior | |
Neves et al. | Immune modulation by MANF promotes tissue repair and regenerative success in the retina | |
Yu-Taeger et al. | Intranasal administration of mesenchymal stem cells ameliorates the abnormal dopamine transmission system and inflammatory reaction in the R6/2 mouse model of Huntington disease | |
Jha et al. | Concentrated conditioned media from adipose tissue derived mesenchymal stem cells mitigates visual deficits and retinal inflammation following mild traumatic brain injury | |
Coll-Miró et al. | Beneficial effects of IL-37 after spinal cord injury in mice | |
Pedicord et al. | Single dose of anti–CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance | |
EP2220214B1 (en) | Method for increasing immunoreactivity | |
de Freria et al. | Neural stem cells: promoting axonal regeneration and spinal cord connectivity | |
Zhang et al. | Mucosal-associated invariant T cells restrict reactive oxidative damage and preserve meningeal barrier integrity and cognitive function | |
Ali et al. | Environmental enrichment enhances systems-level consolidation of a spatial memory after lesions of the ventral midline thalamus | |
DE102012013860A1 (en) | New trypanosome, useful e.g. as vaccine for treating humans and/or animals against e.g. malaria, does not comprise complete functional genome, preferably trypanosome with reduced, incomplete parasitic trypanosomal DNA | |
DE102011111631A1 (en) | Process for the preparation of medicaments for combating tumors | |
Yang et al. | Functionally distinct NPAS4-expressing somatostatin interneuron ensembles critical for motor skill learning | |
DE102021001841A1 (en) | Sensory nucleic acids for the diagnosis and treatment of viral and neoplastic diseases | |
EP2633034B1 (en) | NFkB SIGNAL PATH-MANIPULATED DENDRITIC CELLS | |
Siebenhaar et al. | The search for mast cell and basophil models–are we getting closer to pathophysiological relevance | |
Ito et al. | Plexin-A1 is required for Toll-like receptor‑mediated microglial activation in the development of lipopolysaccharide-induced encephalopathy | |
Ilanges et al. | Microbiota-stimulated Interleukin-22 regulates brain neurons and protects against stress-induced anxiety | |
US20170348393A1 (en) | Treatment of cns inflammatory disorders | |
DE102014001771A1 (en) | Optimized pseudovirions (Ω-virions) as a basis for vaccines and individualized tumor therapy | |
WO2003045428A2 (en) | Use of a technically modified cell as a vaccine for treating tumoral disease | |
Wu et al. | The IL-6-deficient mouse exhibits impaired lymphocytic responses to a vaccine combining live Leishmania major and CpG oligodeoxynucleotides | |
Sharma et al. | Parasitic encephalomyelitis in goats due to aberrant infestation with botfly Oestrous ovis larvae | |
DE3923848C2 (en) | The unmasking training for autologous immunocytes against masked tumor cells in vitro | |
CN109419820B (en) | Application of candida tropicalis in preparation of products for preventing and treating immune system diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R086 | Non-binding declaration of licensing interest | ||
R163 | Identified publications notified | ||
R084 | Declaration of willingness to licence | ||
R012 | Request for examination validly filed | ||
R016 | Response to examination communication |